Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper

Klein R Knudtson MD Lee KE Gangnon R Klein BE The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–1868.

Paulus YM Gariano RF Diabetic retinopathy: a growing concern in an aging population. Geriatrics. 2009;64(2):16–20.

Varma R Bressler NM Doan QV et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–1340.

Klein R Klein BE Moss SE Linton KL The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology. 1992;99(1):58–62.

White NH Sun W Cleary PA et al. DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244–1253.

Bhagat N Grigorian RA Tutela A Zarbin MA Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.

Aiello LP Avery RL Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487.

Zhang X Bao S Lai D Rapkins RW Gillies MC Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas [erratum at https://dx-doi-org.web.bisu.edu.cn/10.2337/db10-er03c]. Diabetes. 2008;57(4):1026–1033.

Leal EC Manivannan A Hosoya K et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48(11):5257–5265.

Melder RJ Koenig GC Witwer BP Safabakhsh N Munn LL Jain RK During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2(9):992–997.

Park HYL Kim JH Park CK Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol. 2014;184(6):1752–1762.

Miyamoto N de Kozak Y Jeanny JC et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2007;50(2):461–470.

Miyamoto N de Kozak Y Normand N et al. PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalmic Res. 2008;40(3-4):203–207.

Nguyen QD De Falco S Behar-Cohen F et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2016Nov 22 doi: 10.1111/aos.13325. [Epub ahead of print].

Kiire CA Porta M Chong V Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol. 2013;58(5):459–465.

Cebeci Z Kir N Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes. 2015;8(8):555–566.

Ciulla TA Harris A McIntyre N Jonescu-Cuypers C Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014;15(7):953–959.

Edelman JL Lutz D Castro MR Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80(2):249–258.

Tamura H Miyamoto K Kiryu J et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–1444.

Felinski EA Antonetti DA Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30(11):949–957.

Semeraro F Morescalchi F Duse S Gambicorti E Cancarini A Costagliola C Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572–584.

Papadopoulos N Martin J Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185.

Brown DM Schmidt-Erfurth U Do DV et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–2052.

Do DV Schmidt-Erfurth U Gonzalez VH et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–1826.

Do DV Nguyen QD Boyer D et al. da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665.

Korobelnik JF Do DV Schmidt-Erfurth U et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.

Korobelnik JF Kleijnen J Lang SH et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmol. 2015;15:52.

Wells JA Glassman AR Ayala AR et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.

Wells JA Glassman AR Jampol LM et al. Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol. 2016a;134(2):127–134.

Wells JA Glassman AR Ayala AR et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016b;123(6):1351–1359.

Jampol LM Glassman AR Bressler NM Wells JA Ayala AR Diabetic Retinopathy Clinical Research Network. Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol. 2016;134(12).

McMillan SS King M Tully MP How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38(3):655–662.

García-Layana A Arias L Figueroa MS et al. A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration. J Ophthalmol. 2014;2014:595132.

De Falco S The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1–9.

Kowalczuk L Touchard E Omri S et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One. 2011;6(3):e17462.

He J Wang H Liu Y Li W Kim D Huang H Blockade of vascular endothelial growth factor receptor 1 prevents inflammation and vascular leakage in diabetic retinopathy. J Ophthalmol. 2015;2015:605946.

Huang H He J Johnson D et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition. Diabetes. 2015;64(1):200–212.

Mitamura Y Tashimo A Nakamura Y et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002;25(12):2352.

Kovacs K Marra KV Yu G et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest Ophthalmol Vis Sci. 2015;56(11):6523–6530.

Carmeliet P Moons L Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–583.

Fauser S Muether PS Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016 pii: bjophthalmol-2015-308264. doi: 10.1136/bjophthalmol-2015-308264. [Epub ahead of print].

Kanda A Noda K Saito W Ishida S Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy. Sci Rep. 2015;5:17946.